#USA #Wheat Ridge #BDC Laboratories #Bill Carlson #Cardiovascular Testing

BDC Laboratories Promotes Bill Carlson as Managing Director

BDC Laboratories, an industry leader in the testing of cardiovascular devices, has made a significant leadership change by appointing Bill Carlson as the new Managing Director. This strategic decision is part of the company's overall objective to enhance its testing capabilities and solidify collaborations within both the industry and academic spheres. Carlson will now oversee the long-term strategic planning for the organization, ensuring that BDC continues to prioritize rigorous, standard-driven testing methodologies.

A Strong Leader with Experience

Joining the company in 2023 as the Director of Sales and Marketing, Carlson brings to the table over three decades of experience in sales, product marketing, and management within the medical device sector. His extensive background in the field positions him well to lead BDC Laboratories through its next phase of growth. Under his guidance, BDC Laboratories aims to further expand its portfolio of accredited testing methodologies, while also enhancing its simulation capabilities and remaining committed to its culture of excellence.

Rich Adams, the CEO of Tentamus North America — the parent company of BDC Laboratories — expressed confidence in Carlson's leadership abilities. Adams noted Carlson combines deep technical expertise with a remarkable knack for understanding customer needs. This skillset will be critical for ensuring that BDC Laboratories meets the requirements of its partners effectively and efficiently.

Partnership with CardioMed Device Consultants

BDC Laboratories is also reinforcing its collaborative efforts by working closely with CardioMed Device Consultants, a recognizable partner within the Tentamus network. This collaboration aims to elevate BDC's testing and simulation capabilities by providing customers with essential regulatory and clinical insights. Through this synergy, the two organizations plan to guide customers through every stage of the product lifecycle — from initial design to market support.

Carlson emphasized the urgency and complexity of the environments their medical device customers operate in, stating, “My primary focus will be to fully grasp their technical hurdles, assist them in navigating various standards, and diversify our solutions to facilitate their innovative endeavors.” This customer-first approach aligns with BDC’s commitment to delivering tailored solutions that support product development.

Achieving New Heights through Strategic Collaborations

One of the prominent steps in Carlson's new role includes capitalizing on recent partnerships and initiatives that enhance the company's testing capabilities. Recently, BDC Laboratories embarked on a strategic collaboration with the Dilawri Cardiovascular Institute (DCI). This partnership is designed to intensify clinically relevant cardiovascular device testing. As part of this strategic effort, BDC Laboratories is equipping DCI's Center for Cardiovascular Translational Science with its advanced HDTi-6000 pulse duplicator. This collaboration emphasizes BDC Laboratories' dedication to bridging the gap between laboratory research and clinical outcomes, thereby facilitating closer relationships with both clinical and industry partners.

About BDC Laboratories

BDC Laboratories specializes in providing comprehensive testing services that enable the mechanical and functional evaluation of Class II and Class III medical device technologies, particularly for regulatory submissions. The company’s services encompass a broad range of offerings, including bioprosthetic valve testing and silicone vascular models, all of which support innovation from early research phases through to market introduction. With Carlson at the helm of leadership, BDC Laboratories is poised to continue its trajectory of growth and positive impact in the cardiovascular device testing domain.